Regenxbio Inc RGNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RGNX is a good fit for your portfolio.
News
-
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
-
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
-
REGENXBIO to Participate in Upcoming Investor Conferences
-
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
-
REGENXBIO Announces Proposed Public Offering of Common Stock
-
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
-
REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
-
REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Trading Information
- Previous Close Price
- $16.11
- Day Range
- $15.32–16.26
- 52-Week Range
- $11.89–28.80
- Bid/Ask
- $15.69 / $17.91
- Market Cap
- $769.48 Mil
- Volume/Avg
- 574,896 / 766,064
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.81
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 344
- Website
- https://www.regenxbio.com
Comparables
Valuation
Metric
|
RGNX
|
CBAY
|
PLRX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.28 | 12.65 | 1.63 |
Price/Sales | 7.81 | 111.01 | 477.92 |
Price/Cash Flow | — | — | — |
Price/Earnings
RGNX
CBAY
PLRX
Financial Strength
Metric
|
RGNX
|
CBAY
|
PLRX
|
---|---|---|---|
Quick Ratio | 2.32 | 10.70 | 17.43 |
Current Ratio | 2.57 | 10.96 | 17.72 |
Interest Coverage | −37.42 | −5.27 | −145.34 |
Quick Ratio
RGNX
CBAY
PLRX
Profitability
Metric
|
RGNX
|
CBAY
|
PLRX
|
---|---|---|---|
Return on Assets (Normalized) | −32.47% | −30.06% | −22.68% |
Return on Equity (Normalized) | −54.67% | −51.97% | −24.50% |
Return on Invested Capital (Normalized) | −43.35% | −30.87% | −28.46% |
Return on Assets
RGNX
CBAY
PLRX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xzmtrpwxr | Cvgz | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xvbxglqrj | Gxmjvf | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nwshqxplf | Pkxkqx | $98.1 Bil | |
MRNA
| Moderna Inc | Skxkxvtr | Ydgxd | $39.1 Bil | |
ARGX
| argenx SE ADR | Lwnpzyr | Hbj | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Lrldbcfzp | Mwxs | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ywwbrkcv | Vyqnd | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ttnprzxg | Qzjqyr | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sffdtxmt | Grqqzd | $12.5 Bil | |
INCY
| Incyte Corp | Pvsnqbxy | Jvszy | $11.9 Bil |